Emerging frontiers in pancreatic cancer research: Elaboration of key genes, cells and the extracellular milieu

Current Opinion in Gastroenterology

Volumn 28, Issue 5, 2012, Pages 516-522

  Kumar Sinha, Chandan ^a   Wei, Iris ^a   Simeone, Diane M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

cancer stem cells; desmoplastic stroma; genetically engineered mouse models of pancreatic cancer; next generation sequencing; pancreatic ductal adenocarcinoma

Indexed keywords

CANCER RESEARCH; CANCER STEM CELL; CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; METASTASIS; NEUROENDOCRINE TUMOR; ONCOGENE; ONCOGENE CDKN2A; ONCOGENE K RAS; ONCOGENE SMAD4; ONCOGENE TP53; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; REVIEW;

ANIMALS; AUTOPHAGY; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICE; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84865469507     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283567f69     Document Type: Review

References (61)

1. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-1806.
2. Mardis ER, Wilson RK. Cancer genome sequencing: a review. Hum Mol Genet 2009; 18:R163-R168.
3. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465:473-477.
4. Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature 2010; 464:993-998.
5. Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature 2010; 463:893-898.
6. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463:191-196.
7. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458:719-724.
8. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-1113.
9. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467:1114-1117.
10. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324:217.
11. Hofstatter EW, Domchek SM, Miron A, et al. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer 2011; 10:225-231.
12. Peterlongo P, Catucci I, Pasquini G, et al. PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. Breast Cancer Res Treat 2011; 126:825-828.
13. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.Mol Cancer Ther 2011; 10:3-8.
14. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011; 3:92ra66.
15. Furukawa T, Kuboki Y, Tanji E, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011; 1:161.
16. Idziaszczyk S, Wilson CH, Smith CG, et al. Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer. Cancer Genet Cytogenet 2010; 202:67-69.
17. Collins MT, Sarlis NJ, Merino MJ, et al. Thyroid carcinoma in the McCune- Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab 2003; 88:4413-4417. (Pubitemid 37153751)
18. Wilson CH, McIntyre RE, Arends MJ, Adams DJ. The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc (Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene 2010; 29:4567-4575.
19. Hsiao HP, Kirschner LS, Bourdeau I, et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab 2009; 94:2930-2937.
20. Bimpaki EI, Nesterova M, Stratakis CA. Abnormalities of cAMP signaling are present in adrenocortical lesions associated with ACTH-independent Cushing syndrome despite the absence of mutations in known genes. Eur J Endocrinol 2009; 161:153-161.
21. Nies C, Bartsch DK, Ehlenz K, et al. Familial ACTH-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia clinically affecting only female family members. Exp Clin Endocrinol Diabetes 2002; 110:277-283. (Pubitemid 35246744)
22. Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340:692-696. (Pubitemid 19214389)
23. Fragoso MC, Latronico AC, Carvalho FM, et al. Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J Clin Endocrinol Metab 1998; 83:2074-2078. (Pubitemid 28496339)
24. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331:1199-1203.
25. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011; 333:425.
26. Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012; 36:173-184.
27. Shain AH, Giacomini CP, Matsukuma K, et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci U S A 2012; 109:E252-E259.
28. Pérez-Mancera PA, Rust AG, Weyden Lvd, et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012. doi: 10.1038/ nature11114. This study describes loss of deubiquitinase USP9X expression (apparently without involving mutations) in pancreatic tumorigenesis.
29. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-1461.
30. Yu M, Tannock IF. Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell 2012; 21:327-329.
31. Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011; 19:429-431.
32. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011; 19:456-469.
33. Ijichi H, Chytil A, Gorska AE, et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 2011; 121:4106-4117.
34. Seton-Rogers S. Pancreatic cancer: Fibroblast co-conspirators. Nat Rev Cancer 2011; 11:758.
35. De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208:469-478.
36. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612-1616.
37. Guerra C, Collado M, Navas C, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011; 19:728-739.
38. McCarthy N. Tumorigenesis: oncogene detox programme. Nat Rev Cancer 2011; 11:622-623.
39. Kong B, MichalskiCW, Erkan M, et al. From tissue turnover to the cell of origin for pancreatic cancer. Nat Rev Gastroenterol Hepatol 2011; 8:467-472.
40. Lonardo E, Hermann PC, Mueller MT, et al. Nodal/Activin signaling drives selfrenewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9:433-446.
41. Donahue TR, Dawson DW. Nodal/Activin signaling: a novel target for pancreatic cancer stem cell therapy. Cell Stem Cell 2011; 9:383-384.
42. Li C, Wu JJ, Hynes M, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011; 141:2218-2227; e5.
43. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148:349-361.
44. Haeno H, Gonen M, Davis MB, et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012; 148:362-375.
45. Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 2012; 148:21-23.
46. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467:1114-1117.
47. Nanda S. Cancer: Pancreatic carcinomas metastasize at a late stage in their development. Nat Rev Gastroenterol Hepatol 2011; 8:4.
48. Kim MJ, Woo SJ, Yoon CH, et al. Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem 2011; 286: 12924-12932.
49. Yang S, Wang X, Contino G, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011; 25:717-729.
50. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-1577.
51. Perez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology 2012; 142:1079-1092.
52. Tuveson D, Hanahan D. Translational medicine: cancer lessons from mice to humans. Nature 2011; 471:316-317.
53. Collins MA, Bednar F, Zhang Y, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012; 122:639-653.
54. Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149:15.
55. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12:4652-4661. (Pubitemid 44297818)
56. Garrido-Laguna I, Uson M, Rajeshkumar NV, et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 2011; 17:5793-5800.
57. Dennis C. Mouse 'avatars' could aid pancreatic cancer therapy. Nature 2012. doi 10.1038/nature.2012.10259.
58. Cruz-Monserrate Z, Abd-Elgaliel WR, Grote T, et al. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Gut 2011.
59. Eser S, Messer M, Eser P, et al. In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc Natl Acad Sci U S A 2011; 108:9945-9950.
60. Bausch D, Thomas S, Mino-Kenudson M, et al. Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res 2011; 17:302-309.
61. Collisson E, Tempero M. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin Cancer Res 2011; 17:203-205.